You are here:

MS in the Media - 16 October 2020

Published on

On this page

  1. Siponimod approved for SPMS
  2. MS differences by gender and disease type
  3. Factors affecting MS and employment explored

10 - 16 October 2020

These are links to recent news stories about multiple sclerosis that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter, or regular email alerts.

Siponimod approved for SPMS

Siponimod (Mayzent), a drug for active secondary progressive MS that reduces the number of relapses and slows the build up of disability, has been approved for use on the NHS in England, Wales and Scotland.

Source: NICE
Source: MS News Today

MS Trust link: Siponimod (Mayzent) approved for active secondary progressive MS

MS differences by gender and disease type

Women with MS are more likely to be affected by pain, depression and cognitive symptoms than men, according to research based on the German MS Register. Other symptoms are more associated with type of MS than gender - visual and sensory problems were more common in relapsing MS and problems with walking, spasticity and ataxia occurred more often in progressive MS

Source: AJMC

MS Trust link: MS symptoms

Factors affecting MS and employment explored

The risk of stopping working is high in MS, particularly in the first years after diagnosis, according to a US study. People at risk of unemployment were more likely to have a progressive MS, fatigue, sleep problems, pain, anxiety and depression. They were also more likely to feel they lacked control of their situation than people with MS who remained in work

Source: MS News Today

MS Trust link: Working life

 

Print this page